HLA class I histocompatibility antigen, A-11 alpha chain (HLA-A11)

HLA class I histocompatibility antigen, A-11 alpha chain is a highly polymorphic human leukocyte antigen (HLA) that belongs to the major histocompatibility complex (MHC) class I family. It is primarily responsible for presenting endogenous peptides, derived from cytosolic proteins such as viral or tumor-associated antigens, to CD8+ cytotoxic T lymphocytes (CTLs). This presentation is a fundamental step in the adaptive immune response, enabling the immune system to identify and destroy infected or malignant cells. HLA-A11 is particularly prevalent in East Asian populations and has been linked to the immune control of various pathogens, including Hepatitis B virus (HBV), Epstein-Barr virus (EBV), and HIV. In the context of modern oncology, HLA-A11 serves as a critical therapeutic target for personalized immunotherapies, including TCR-engineered T cell therapies and neoantigen vaccines targeting common mutations like KRAS G12V. However, the efficacy of these treatments can be limited by tumor-mediated HLA down-regulation and the potential for off-target immune responses against self-antigens.

Other names

HLA-A*11HLA-A*11:01MHC class I antigen HLA-A heavy chainHuman leukocyte antigen A11HLAALeukocyte antigen class I-A

HLA-A11 functions as a restriction element that presents specific intracellularly processed peptides (8-13 amino acids) to the alpha-beta T cell receptor (TCR) on CD8-positive cytotoxic T cells. Therapeutic agents like TCR-T cells are engineered to recognize these specific peptide-HLA-A11 complexes on the surface of target cells, while vaccines provide the necessary antigens to be loaded onto HLA-A11 to prime an endogenous immune response.